GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dermapharm Holding SE (XTER:DMP) » Definitions » EV-to-EBITDA

Dermapharm Holding SE (XTER:DMP) EV-to-EBITDA : 9.03 (As of Jun. 01, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Dermapharm Holding SE EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Dermapharm Holding SE's enterprise value is €2,765 Mil. Dermapharm Holding SE's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was €306 Mil. Therefore, Dermapharm Holding SE's EV-to-EBITDA for today is 9.03.

The historical rank and industry rank for Dermapharm Holding SE's EV-to-EBITDA or its related term are showing as below:

XTER:DMP' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.97   Med: 10.67   Max: 21.78
Current: 9.02

During the past 12 years, the highest EV-to-EBITDA of Dermapharm Holding SE was 21.78. The lowest was 4.97. And the median was 10.67.

XTER:DMP's EV-to-EBITDA is ranked better than
68.71% of 735 companies
in the Drug Manufacturers industry
Industry Median: 14.08 vs XTER:DMP: 9.02

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-06-01), Dermapharm Holding SE's stock price is €35.05. Dermapharm Holding SE's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was €1.920. Therefore, Dermapharm Holding SE's PE Ratio (TTM) for today is 18.26.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Dermapharm Holding SE EV-to-EBITDA Historical Data

The historical data trend for Dermapharm Holding SE's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dermapharm Holding SE EV-to-EBITDA Chart

Dermapharm Holding SE Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.45 14.57 5.69 12.08 9.19

Dermapharm Holding SE Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.31 6.10 5.86 9.19 6.02

Competitive Comparison of Dermapharm Holding SE's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Dermapharm Holding SE's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dermapharm Holding SE's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dermapharm Holding SE's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Dermapharm Holding SE's EV-to-EBITDA falls into.


;
;

Dermapharm Holding SE EV-to-EBITDA Calculation

Dermapharm Holding SE's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=2764.820/306.305
=9.03

Dermapharm Holding SE's current Enterprise Value is €2,765 Mil.
Dermapharm Holding SE's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €306 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dermapharm Holding SE  (XTER:DMP) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Dermapharm Holding SE's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=35.05/1.920
=18.26

Dermapharm Holding SE's share price for today is €35.05.
Dermapharm Holding SE's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.920.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Dermapharm Holding SE EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Dermapharm Holding SE's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Dermapharm Holding SE Business Description

Traded in Other Exchanges
Address
Lil-Dagover-Ring 7, Grunwald, BY, DEU, 82031
Dermapharm Holding SE manufactures patent-free branded pharmaceuticals for selected therapy fields, over-the-counter drugs, and natural remedies. The portfolio of the company includes cosmetics, nutritional supplements, and diet and medical devices. Business operating segments include Branded pharmaceuticals, which drive key revenue, Other healthcare products, and Parallel import business. The Branded pharmaceuticals segment covers numerous product areas through a wide variety of items sold under reputable brand names.
Executives
Wilhelm Beier Supervisory Board
Dr. Hans-georg Feldmeier Board of Directors
Christof Dreibholz Board of Directors
Lothar Lanz Supervisory Board
Anja Schorn Board Member Themis Beteiligungs-AG
Hilde Neumeyer Board of Directors

Dermapharm Holding SE Headlines

No Headlines